Biotechnology - Licensing, North America

Filter

Current filters:

LicensingNorth America

Popular Filters

ADC Therapeutics signs license agreement with Five Prime

ADC Therapeutics signs license agreement with Five Prime

05-11-2013

Swiss ADC Therapeutics, a portfolio company of Auven Therapeutics, and Five Prime Therapeutics (NASDAQ:…

ADC TherapeuticsBiotechnologyEuropeLicensingNorth AmericaOncology

Gliknik enters licensing agreement with Pfizer

30-09-2013

Gliknik has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, which is…

BiotechnologyGliknikImmunologicalsLicensingNorth AmericaOncologyPfizer

Agenus and VaxLogic licensing accord on QS-21 Stimulon adjuvant

Agenus and VaxLogic licensing accord on QS-21 Stimulon adjuvant

27-09-2013

US biotech firm Agenus has entered into a non-exclusive license agreement with VaxLogic, a subsidiary…

AgenusBiotechnologyLicensingNorth AmericaPharmLogicVaccinesVaxLogic

Amgen's US deal with Servier cleared

13-08-2013

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Amgen gains rights to Servier's heart drugs ivabradine and S38844

10-07-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Emergent BioSolutions gets exclusive US commercial rights to pandemic flu vaccine candidate

31-12-2012

US vaccine maker Emergent BioSolutions (NYSE: EBS) has signed a license agreement with fellow USA-based…

BiotechnologyEmergent BioSolutionsLicensingNorth AmericaVaccinesVaxInnate Corp

News briefs: Celgene deal with Sutro; Amgen pleads guilty to misbranding

19-12-2012

US biotech firm Celgene Corp (Nasdaq: CELG) has entered a collaboration with San Francisco-based Sutra…

AmgenAranespBiotechnologyCelgeneFinancialLegalLicensingNorth AmericaSutro Biopharma

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

VentiRx collaborates with Celgene on cancer drug candidate; pomalidomide update

05-10-2012

VentiRx Pharmaceuticals, a privately held US biopharmaceutical company dedicated to the development of…

BiotechnologyCelgeneLicensingNorth AmericaOncologyPharmaceuticalpomalidomideRegulationVentiRx PharmaceuticalsVTX-2337

COMPANY SPOTLIGHT

Menarini

Back to top